Descrizione del progetto
Ridurre la resistenza a un trattamento importante per la tubercolosi
Le malattie infettive sono provocate da batteri, virus, funghi e parassiti. Esistono vaccini per prevenire l’infezione o farmaci per uccidere i microrganismi, ma un numero crescente di microrganismi sta diventando resistente ai trattamenti. La tubercolosi (TBC) è provocata da Mycobacterium tuberculosis. In molti casi, questi batteri sono resistenti a più farmaci, alcuni con risultati letali. Il progetto TRIC-TB, finanziato dall’UE, sta esplorando un modo promettente per aumentare l’efficacia del trattamento per la tubercolosi multi-resistente. Concentrandosi sul ripristino della sensibilità a una linea di trattamento esistente, gli scienziati sperano di migliorare i risultati dei pazienti indipendentemente dallo stato di resistenza iniziale al momento dell’infezione.
Obiettivo
Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year. In 2016, 480’000 of TB cases were multidrug-resistant (MDR-TB) and 9% percent of those cases are extensively drug-resistant (XDR), with mortality rates as high as 70%. Ethionamide (ETH) is a vital part of the WHO essential medicines list of 2nd-line TB therapy for MDR-TB, however, ETH suffers from significant levels of resistance and side effects at current dosing levels. BVL-GSK038 and BVL-GSK098 are proprietary to BioVersys/GlaxoSmithKline and have been developed through an extensive Lead Optimization program with collaborators from Lille University. Low doses of both compounds fully restore and “boost” the activity of ETH to rapidly kill Mycobacterium tuberculosis (Mtb) including MDR strains at significantly lower doses of ETH than previously reported, thus making MDR-TB sensitive to ETH once again. Through a comprehensive IND enabling package including in vitro and in vivo assessment of ETH with BVL-GSK038 and BVL-GSK098, including PK/PD, resistance development, safety, mechanism of action and synergistic studies with different drug compound combinations and then first in human clinical studies the consortium aims to:
i) Define the future placement of a boosted ETH (ETH + BVL-GSK038 or BVL-GSK098) in a universal TB treatment regimen, including overcoming MDR-TB with improved safety, time to cure and relapse rates;
Ultimately, we expect to identify a new and clinically proven TB regimen that leads to better patient outcomes independently of the starting resistance status of the TB infection. The TB and wider scientific communities will benefit from an improved understanding of ETH and the exploration of a novel class of therapeutic compounds acting on transcriptional modulators (BVL-GSK038 and BVL-GSK098).
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
H2020-JTI-IMI2-2018-16-single-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
4057 Basel
Svizzera
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.